ABL Bio Inc. (KOSDAQ:298380)

South Korea · Delayed Price · Currency is KRW

106,600

+17,900 (20.18%)

Jun 29, 2026, 3:30 PM KST

62.75% (1Y)

Market Cap	5.97T +52.4%
Revenue (ttm)	90.32B +226.9%
Net Income	-24.14B
EPS	-452.97
Shares Out	55.99M
PE Ratio	n/a
Forward PE	23,873.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	894,918
Open	90,100
Previous Close	88,700
Day's Range	90,100 - 108,000
52-Week Range	60,700 - 257,500
Beta	0.21
Analysts	Buy
Price Target	257,500.00 (+141.56%)
Earnings Date	Aug 11, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatm... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 2016

Employees 102

Stock Exchange KOSDAQ

Ticker Symbol 298380

Full Company Profile

Financial Performance

In 2025, ABL Bio's revenue was 79.35 billion, an increase of 137.55% compared to the previous year's 33.40 billion. Losses were -37.81 billion, -31.92% less than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 298380 stock is "Buy." The 12-month stock price target is ₩257,500, which is an increase of 141.56% from the latest price.

Price Target

₩257,500

(141.56% upside)

Analyst Consensus: Buy

Stock Forecasts